James Huang has joined Vivo Ventures as an executive-in-residence. He will work with the firm's existing portfolio companies, and held expand its presence in
“We are excited about James coming on board and what he will be able to bring to Vivo,” said Frank Kung, Managing Partner of Vivo Ventures. “His extensive relationships throughout the pharmaceutical industry, his impressive track record in closing multiple business development partnerships, and his experience in building companies make him a valuable asset to our team and our portfolio companies.”
“Vivo Ventures is one of the best recognized life sciences venture firms in the
About James Huang
With 20 years of experience in the pharmaceutical industry, James joins Vivo from Anesiva, where he has served as president since September 2005. Previously, he had served as Anesiva's senior vice president of business development and commercial operations.
He joined Anesiva from Tularik Inc., where he held the position of vice president of business development and commercial operations and led the development and negotiation of commercial and scientific collaborations, alliances, and licensing agreements. Among the most notable include: a collaboration with Medarex to develop and commercialize human therapeutic antibodies; a collaboration with Sankyo to jointly discover and develop human therapeutics related to orphan G-protein coupled receptors (GPCRs); as well as other technology collaborations and corporate development acquisitions. Mr. Huang also guided strategic planning and execution for Tularik's marketing programs.
Prior to Tularik, Mr. Huang was product director of Avandia and diabetes at SmithKline Beecham PLC (now GlaxoSmithKline) where he launched Avandia (rosiglitazone maleate), which achieved over $2 billion in
Mr. Huang also held various positions in Bristol-Myers Squibb's Worldwide Strategic Product Planning, Managed Care and Sales and Marketing organizations, and research and development positions at Alza Corporation (now a Johnson & Johnson company).
He received an M.B.A. from Stanford Graduate School of Business and earned a B.S. degree in Chemical Engineering at the
About Vivo Ventures
Vivo Ventures is a venture capital firm focused on the life sciences formed in 1996 with over $650M under management. With over 90 years of scientific and operational expertise in biotechnology, Vivo helps its portfolio companies develop corporate strategy, arrange licensing agreements and strategic alliances, recruit key management personnel, and acquire new products and technology to accelerate growth. Its current portfolio includes more than 60 private and public biotechnology companies in the areas of biopharmaceuticals, specialty pharmaceuticals, and medical devices. For more information, visit http://www.vivoventures.com .